Carsten Linnemann, Ph.D., CEO of Neogene Therapeutics and Head of Oncology Cell Therapy Clinical Development, AstraZeneca joins Cell & Gene: The Podcast’s Erin Harris to discuss T-cell receptor (TCR) ...

As professionals within the life sciences industry, a new era is upon us, marked by the pursuit of efficiency. In part this has been driven by legislative measures such as the Inflation Reduction Act ...

In the second article in a series on the leadership benefits of putting employees first, Christine Miller, president and CEO ...

What does the ICF amendment or revision process look like within a digital platform and is this harder or easier than traditional paper-based approaches? Paper consent revisions involve updating forms ...

Stop spending thousands of man-hours on SDTM, ADaM and TFL generation and accelerate the delivery of clinical discoveries to patients. Transform your biostatistics deliveries with ThoughtSphere.

Part one of a two-part series that identifies current uses of AI in drug discovery and development and assesses whether AI ...

An LLC model in biotech brings specific advantages, such as streamlined deal-making, IP ownership, and capital reinvestment ...

It wouldn't be accurate to say that surgeon-turned-healthcare investment banker and consultant Dr. Ali Pashazadeh traded his scalpels for spreadsheets. In fact, he still wields a scalpel quite ...

What do Annovis Bio’s buntanetap, Pfizer’s Viagra, and Lilly’s GLP-1 drug Trulicity have in common? They could all end up being used together in combination as a new treatment focused on improving ...